Why the outcome of a pre-trial hearing could prove good news for GSK
Shares in global bio-pharmaceutical firm GSK (GSK) have performed poorly in recent times, relatively speaking, lagging the FTSE 100 index by 4% and peer AstraZeneca (AZN) by a whopping 87% over the last five years.Operationally...
18 January 2024